- Positive data show high sensitivity and specificity in the
detection of Lymphoma and Hemangiosarcoma as Volition remains on
target for launch of its first product expected later this
year
- Cancer is the most common cause of death in dogs over the age
of two years old in the U.S.
- Together, Lymphoma and Hemangiosarcoma make up approximately
one-third of canine cancers
AUSTIN, Texas, Oct. 16, 2020 /PRNewswire/ -- VolitionRx
Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national
epigenetics company developing simple, easy to use, cost effective
blood tests to help diagnose a range of cancers and other diseases
in both humans and animals, is presenting two abstracts with
new data on its first product, the Nu.Q™ Vet Cancer Screening Test,
at the 2020 Veterinary Cancer Society (VCS) Virtual Annual
Conference, which takes place from Thursday,
October 15 through Saturday, October 17.
"The data demonstrate that the Nu.Q™ Vet Cancer Screening Test
has a high sensitivity and specificity in relation to both Lymphoma
and Hemangiosarcoma detection in a large and varied cohort," said
Heather Wilson-Robles, Professor at
Texas A&M University, Chief Medical
Officer of Volition Veterinary Diagnostics Development LLC, and
President-Elect of the VCS. "The results show an Area Under the
Curve (AUC) of 87.3% and 97.6%, respectively, for Lymphoma and
Hemangiosarcoma.
Dr. Robles added, "These positive findings provide us with real
confidence as we move forward towards the launch of our first
product, the Nu.Q™ Vet Cancer Screening Test, anticipated in the
coming weeks. Early diagnosis has a huge potential to help improve
the treatment and the quality of life for dogs as well as providing
valuable additional information to inform the clinical
decision-making process."
An interview with Heather Wilson-Robles, Chief Medical Officer of
Volition Veterinary Diagnostics Development LLC.
Cancer is the most common cause of death in dogs over the age of
two years old in the U.S. and up to 50% of all dogs over the age of
10 develop cancer in their lifetime. Together, Lymphoma and
Hemangiosarcoma make up approximately one third of canine cancers.
Currently, dogs suspected of having cancer are required to undergo
a variety of diagnostic tests that may be expensive, time consuming
and/or painful for the animal. The Nu.Q™ Vet Cancer Screening Test
is a low-cost, easy to use ELISA-based screening test that measures
and identifies circulating nucleosomes, which are early markers of
cancer, from a simple blood sample to enable a streamlined and less
invasive diagnostic process.
The studies were carried out at Texas
A&M University on 334 samples (Healthy Control n=134,
Lymphoma n=127, Hemangiosarcoma n=73) which included a variety of
breeds, genders, weights, ages and different cancer stages.
The Abstracts
Characterizing Circulating Nucleosomes in the Plasma of Dogs
with Lymphoma
Friday, October
16 at 1:30 p.m. Eastern
Time
Characterizing Circulating Nucleosomes in the Plasma of Dogs
with Hemangiosarcoma
Saturday,
October 17 at 11:15 a.m. Eastern
Time
To register for the 2020 Virtual Veterinary Cancer Society
Annual Conference please click here.
The abstracts will be posted to the Volition website on
Monday October 19.
To learn more about Volition Veterinary and Nu.Q™ Vet please
visit our new webpage at
https://volition.com/veterinary and/or register for
Volition's Capital Markets Day presentation on Tuesday, October 20 at 8:00 a.m. Eastern Time here.
About Volition
Volition is a multi-national epigenetics company developing
simple, easy to use, cost effective blood tests to help diagnose a
range of cancers and other diseases. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. The tests are based on the science
of NucleosomicsTM, which is the practice of identifying
and measuring nucleosomes in the bloodstream or other bodily fluid
- an indication that disease is present. Volition is primarily
focused on human diagnostics but also has a subsidiary focused on
animal diagnostics.
Volition's research and development activities are centered in
Belgium, with additional offices
in Texas, London and Singapore, as the company focuses on bringing
its diagnostic products to market.
NucleosomicsTM and Nu.Q™ and their respective logos
are trademarks of Volition and its subsidiaries.
For more information about Volition, visit Volition's website
(http://www.volition.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Batchelor,
Volition
mediarelations@volition.com
+44 (0)7557
774620
|
Scott Powell,
Volition
investorrelations@volition.com
+1 (646) 650
1351
|
Jen Lewis,
Pegasus
jen.lewis@thisispegasus.co.uk
+44 (0)7809
867943
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the timing of the commercial launch of Volition's test platforms
for early detection of cancer and other diseases. Volition's actual
results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests. For instance, if Volition fails to develop
and commercialize diagnostic or prognostic products, it may be
unable to execute its plan of operations. Other risks and
uncertainties include Volition's failure to obtain necessary
regulatory clearances or approvals to distribute and market future
products; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic or
prognostic products Volition might develop; Volition's failure to
secure adequate intellectual property protection; Volition will
face fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
market and its rapid technological change; downturns in domestic
and foreign economies; and other risks identified in Volition's
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/volition-veterinary-diagnostics-development-llc-announces-product-data-regarding-its-nuq-vet-cancer-screening-test-in-lymphoma-and-hemangiosarcoma-to-be-presented-at-the-2020-vcs-virtual-annual-conference-301153913.html
SOURCE VolitionRx Ltd